According to this publication, when DOX was administered with another drug that has a synergistic effect with it, side effect markers decreased in the HER2-positive breast cancer cell line, while such an effect was not observed in the MCF-7 cell line [27]. This evidence concerns the gene ERBB2 and breast carcinoma.